Immunological Correlates of Vaccine Breakthrough Infections Caused by SARS-CoV-2 Variants in Highly C-19 Vaccinated Populations

In highly C-19 vaccinated populations, an increase in IgG4 Ab titers following SIR-enabling PNNAb-dependent VBTIs with infectious SC-2 immune escape variants promoted generalized hyposensitization to ‘foreign’ and hypersensitization to ‘self’. Whereas hyposensitization to ‘foreign’ has an anti-inflammatory effect, thereby mitigating disease symptoms, hypersensitization to ‘self’ promotes carcinogenicity and autoreactivity.     

You can buy and download my latest article of 42 pages as a booklet, bringing you brand new insights not ever published before

I want the article

GEERT VANDEN BOSSCHE

Geert Vanden Bossche received his DVM from the University of Ghent, Belgium, and his PhD degree in Virology from the University of Hohenheim, Germany. He held adjunct faculty appointments at universities in Belgium and Germany. After his career in Academia, Geert joined several vaccine companies (GSK Biologicals, Novartis Vaccines, Solvay Biologicals) to serve various roles in vaccine R&D as well as in late vaccine development.

Geert then moved on to join the Bill & Melinda Gates Foundation’s Global Health Discovery team in Seattle (USA) as Senior Program Officer; he then worked with the Global Alliance for Vaccines and Immunization (GAVI) in Geneva as Senior Ebola Program Manager. At GAVI he tracked efforts to develop an Ebola vaccine. He also represented GAVI in fora with other partners, including WHO, to review progress on the fight against Ebola and to build plans for global pandemic preparedness.

Back in 2015, Geert scrutinized and questioned the safety of the Ebola vaccine that was used in ring vaccination trials conducted by WHO in Guinea. His critical scientific analysis and report on the data published by WHO in the Lancet in 2015 was sent to all international health and regulatory authorities involved in the Ebola vaccination program. After working for GAVI, Geert joined the German Center for Infection Research in Cologne as Head of the Vaccine Development Office. He is at present primarily serving as a Biotech / Vaccine consultant while also conducting his own research on Natural Killer cell-based vaccines.

.Â